Glaukos (GKOS) Competitors

Zimmer Biomet (NYSE:ZBH) and Glaukos (NYSE:GKOS) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, media sentiment, valuation and risk.

Do institutionals and insiders hold more shares of ZBH or GKOS?

88.9% of Zimmer Biomet shares are owned by institutional investors. Comparatively, 99.0% of Glaukos shares are owned by institutional investors. 1.4% of Zimmer Biomet shares are owned by insiders. Comparatively, 5.8% of Glaukos shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Is ZBH or GKOS more profitable?

Zimmer Biomet has a net margin of 10.51% compared to Glaukos' net margin of -21.43%. Zimmer Biomet's return on equity of 12.76% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zimmer Biomet	10.51%	12.76%	7.21%
Glaukos	-21.43%	-8.59%	-6.61%

Do analysts recommend ZBH or GKOS?

Zimmer Biomet presently has a consensus price target of $112.89, suggesting a potential upside of 14.77%. Glaukos has a consensus price target of $118.00, suggesting a potential upside of 34.78%. Given Glaukos' stronger consensus rating and higher possible upside, analysts plainly believe Glaukos is more favorable than Zimmer Biomet.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zimmer Biomet	2 Sell rating(s)	8 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.48
Glaukos	2 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.69

Which has better earnings & valuation, ZBH or GKOS?

Zimmer Biomet has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Zimmer Biomet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zimmer Biomet	$7.68B	2.54	$903.70M	$4.11	23.93
Glaukos	$383.48M	13.09	-$146.37M	-$1.65	-53.06

Which has more volatility and risk, ZBH or GKOS?

Zimmer Biomet has a beta of 0.67, suggesting that its stock price is 33% less volatile than the S&P 500. Comparatively, Glaukos has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500.

Does the media prefer ZBH or GKOS?

In the previous week, Zimmer Biomet had 12 more articles in the media than Glaukos. MarketBeat recorded 21 mentions for Zimmer Biomet and 9 mentions for Glaukos. Zimmer Biomet's average media sentiment score of 0.76 beat Glaukos' score of 0.11 indicating that Zimmer Biomet is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zimmer Biomet	10 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Glaukos	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Zimmer Biomet beats Glaukos on 9 of the 16 factors compared between the two stocks.